NEWSROOM

Biotechnology

Oncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study

Oncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study

Aug 12, 2024

Case Series represents second study showing VitaGraft Kidney as a measure of response to the benefit of therapy for one leading cause of allograft failure IRVINE, Calif., August 12, 2024 — Oncocyte Corp. (Nasdaq: OCX), a molecular diagnostics technology company, announced the recent publication of a case series of two kidney transplant patients who were monitored for antibody-mediated rejection (AMR) using its proprietary VitaGraft™ Kidney diagnostic test. Patients were tested before, during...

Lipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical Trial

Lipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical Trial

Aug 12, 2024

Top Line Data Expected Year-End 2024 Pittsburgh, August 12, 2024 -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us,” “we” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces the dosing of the first two patients with LP-310 in its Phase 2a clinical trial in Oral Lichen Planus (OLP) patients. Lipella’s Phase 2a trial is a multicenter, dose-ranging study involving adult male and female subjects...

ANEW MEDICAL, INC. Pursues Neurological Approach to Treating Weight Loss and Eating Disorders through Melanocortin Receptor Binding Peptides

ANEW MEDICAL, INC. Pursues Neurological Approach to Treating Weight Loss and Eating Disorders through Melanocortin Receptor Binding Peptides

Aug 9, 2024

Melanocortin receptors on neurons in the brain control feeding and weight loss Patented peptide molecules delivered orally as a pill can control feeding disorders and weight loss NEW YORK, NY, August 09, 2024 - ANEW MEDICAL, INC. (NASDAQ: WENA) has announced that, as a result of its worldwide licensing agreement with Teleost Biopharmaceuticals and the University of Arizona, it plans to pursue the development of therapeutics using novel proprietary peptides that selectively bind and activate...

Oncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study

Oncocyte Announces Successful GraftAssure Beta Launch and Q2 2024 Results

Aug 8, 2024

Interest in kidney transplant assay represents approximately 25% of US transplant volume Company lays out land and expand strategy in transplant IRVINE, Calif., August 8, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published its second quarter 2024 results and the following letter to shareholders. Dear shareholders, We are thrilled to report that we have successfully launched GraftAssureTM, which is our research-use-only assay that can detect...

ANEW MEDICAL, INC. Pursues Neurological Approach to Treating Weight Loss and Eating Disorders through Melanocortin Receptor Binding Peptides

ANEW MEDICAL, INC. Announces Patents Issued in Major Asian Markets for use of Genetic Therapy in the Treatment of Alzheimer’s Disease and ALS

Aug 8, 2024

Patents issued in mainland China protect the Company’s novel secreted Klotho protein and Its gene delivery system Recent Patents issued in Hong Kong and Shanghai support protection to develop treatments for Alzheimer’s Disease and other neurodegenerative diseases New York, NY, August 8, 2024 - ANEW MEDICAL, INC. (“ANEW” or “the Company”) (NASDAQ: WENA) a US-based biotechnology company focused on developing cell- and gene-based treatments to affect aging and age-related diseases, announces the...

Oncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study

Oncocyte Announces August Investor Conferences Participation

Aug 5, 2024

IRVINE, Calif., August 5, 2024 — Oncocyte Corp. (Nasdaq: OCX), a molecular diagnostics technology company, today announced that CEO Josh Riggs and CFO Andrea James plan to participate in the following investor conferences in August: 9th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference, August 12-13, 2024. Oncocyte management plans to host meetings with investors. Sidoti Micro-Cap Virtual Conference, August 14-15, 2024. The company is scheduled to present on Wednesday, August 14,...

Lipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical Trial

Lipella Pharmaceuticals Announces Closing of $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules

Aug 1, 2024

PITTSBURGH, PA, August 1, 2024 – Lipella Pharmaceuticals Inc. (“Lipella” or the “Company”) (Nasdaq: LIPO), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced that it has closed its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of an aggregate of 2,066,000 shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $0.62 per share (or...

Oncocyte to Announce Second Quarter 2024 Financial Results on August 8

Oncocyte to Announce Second Quarter 2024 Financial Results on August 8

Aug 1, 2024

Conference Call and Webcast on Thursday, August 8, 2024 at 2:00 p.m. PT / 5:00 p.m. ET IRVINE, Calif., Aug 1, 2024 - Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, announced today that the company will release its second quarter 2024 financial results on Thursday, August 8, 2024, after U.S. market close. The company will host a conference call and webcast on Thursday, August 8, 2024, at 5:00 p.m. Eastern Time to discuss its financial results and highlights. Interested parties...

Lipella Pharmaceuticals Announces $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules

Lipella Pharmaceuticals Announces $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules

Aug 1, 2024

PITTSBURGH, PA, August 1, 2024 – Lipella Pharmaceuticals Inc. (“Lipella” or the “Company”) (Nasdaq: LIPO), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 2,066,000 shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $0.62 per share (or pre-funded warrant in lieu thereof) in a registered direct offering...

Phytanix Bio Publishes New Investor Deck Highlighting Strategic Vision and Growth Potential

Phytanix Bio Publishes New Investor Deck Highlighting Strategic Vision and Growth Potential

Jul 30, 2024

NEW YORK and SANTA BARBARA, Calif., July 30, 2024 - Phytanix Bio, a pioneering preclinical stage pharmaceutical company dedicated to the development of therapeutics based on cannabinoid and cannabinoid-like molecules, today announced the release of its new investor deck. The updated presentation provides an in-depth look at the company’s strategic vision, scientific advancements, and growth potential as it progresses towards the development of next-generation cannabinoid medicines. The...

Lipella Pharmaceuticals Announces $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules

Lipella Pharmaceuticals Initiates Phase 2a Trial for LP-310 in Oral Lichen Planus, Enrolls First Patients

Jul 29, 2024

Top Line Data Expected Year-End 2024 Pittsburgh, July 29, 2024 -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced the enrollment of the first patients in its multi-center Phase 2a clinical trial evaluating LP-310 for the treatment of Oral Lichen Planus (OLP). This chronic inflammatory condition, which affects over 6 million Americans, is characterized by...

Chain Bridge I to Acquire Phytanix Bio, Creating a New Public Company Focused on Developing Next Generation Cannabinoid and Cannabinoid-like Medicines

Chain Bridge I to Acquire Phytanix Bio, Creating a New Public Company Focused on Developing Next Generation Cannabinoid and Cannabinoid-like Medicines

Jul 22, 2024

Phytanix Bio is a preclinical stage pharmaceutical company founded by former members and associates of GW Pharmaceuticals, holding exclusive cannabinoid and cannabinoid-like medicine intellectual property (IP) The transaction reflects a pre-deal valuation of $58 million for Phytanix Bio plus the assumption of $17 million of preferred stock and $4.4 million of short-term debt that will be exchanged for convertible preferred stock at deal close The business combination is expected to be...

ANEW MEDICAL to Advance Patented Klotho Gene Therapy for Neurodegenerative Disorder Treatments

ANEW MEDICAL to Advance Patented Klotho Gene Therapy for Neurodegenerative Disorder Treatments

Jul 9, 2024

Genomics data suggests having an active Klotho gene sequence may help people live longer, healthier lives The Company was granted patents in Europe, China, and Hong Kong and awaits issuance of patents in the U.S. and Canada NEW YORK, July 9, 2024 -- ANEW MEDICAL, INC. (NASDAQ: WENA) (“ANEW”), a biopharmaceutical company specializing in the advancement of novel disease-modifying therapies for neurological and age-related disorders, announces plans to advance its recently patented Klotho gene...

Prospects for the Development of the Biofuels Industry in Brazil: Sustainable Future and Growth Opportunities

Prospects for the Development of the Biofuels Industry in Brazil: Sustainable Future and Growth Opportunities

Jul 2, 2024

New York, July 2, 2024 - VoStock Capital in cooperation with Biofuels Brazil (International Investment Forum) is thrilled to invite you to the free webinar devoted to Prospects for the development of the industry of Biofuels Brazil.The webinar will be held on July 5th at 3 pm (UTC-3) São Paulo, Brazil time. The webinar will be held in English. Register for the free webinar The webinar will feature distinguished experts as speakers: Ruy Campos Dugone, Executive Director of Green Cross...

ANEW MEDICAL Forms Strategic Partnership with Japan’s Okinawa Research Center for Longevity Science (ORCLS) to Study Klotho Gene

ANEW MEDICAL Forms Strategic Partnership with Japan’s Okinawa Research Center for Longevity Science (ORCLS) to Study Klotho Gene

Jun 27, 2024

Collaboration focuses on research and development of ANEW’s patented Klotho gene therapy in enhancing longevity and reducing age-related diseases ANEW’s mission is to deliver transformative protein, cell, and gene therapies in areas of high unmet medical needs, particularly targeting highly prevalent neurodegenerative diseases and age-related disorders NEW YORK, June, 27. 2024 -- ANEW MEDICAL, INC. (Nasdaq: WENA), a biopharmaceutical company specializing in the advancement of novel...

ANEW MEDICAL, INC. Secures Key Patent in Europe for HUMAN Klotho Gene RNA Slice Variant and Protein

ANEW MEDICAL, INC. Secures Key Patent in Europe for HUMAN Klotho Gene RNA Slice Variant and Protein

Jun 26, 2024

ANEW to explore therapeutics and specialty diagnostics utilizing the s-KL protein and will pursue other medical product development and commercial opportunities of interest Exclusive, worldwide intellectual property licensed from Universitat Autònoma de Barcelona (UAB) and Institució Catalana de Recerca i Estudis Avançats (ICREA) in Barcelona, Spain NEW YORK, June 26, 2024 - ANEW MEDICAL, INC. (NASDAQ: WENA) (“ANEW” or “the Company”) a biopharmaceutical company specializing in the advancement...

Rodedawg (OTC: RWGI) Launches TikTok Shop to Expand into Global E-Commerce Market

Rodedawg (OTC: RWGI) Launches TikTok Shop to Expand into Global E-Commerce Market

Jun 12, 2024

Company E-commerce Effort Expands into 10 Billion Dollar Marketplace COSTA MESA, CA, June 12th, 2024 – Rodedawg International Industries, Inc. (OTC: RWGI), a prominent cannabis manufacturer and distributor, is excited to announce the launch of its own TikTok Shop. This strategic move aims to leverage the booming e-commerce potential on TikTok, expanding Rodedawg's market reach and driving sales of its popular product lines. The initial product offering is the All natural Elixicure Topical Pain...

SIPP Industries Announces Strategic R&D Agreement with Calypso Pharmaceuticals to Develop Nano-Emulsified Topical Targeting Melanoma

Jun 11, 2024

Costa Mesa, CA, June 11, 2024 - SIPP Industries, Inc. (OTC: SIPC), a multifaceted corporation specializing in the manufacturing and distribution of commercial and consumer products in the cannabis industry, is pleased to announce a Research and Development agreement with Calypso Pharmaceuticals. The aim is to create a nano-emulsified topical formulation in collaboration with AVEINA, SIPP's wellness-focused brand specializing in nanotechnology formulations, to target melanoma using Peptide...

Breakthrough in Kidney Transplant Monitoring: PRISM MarketView Spotlights Oncocyte’s VitaGraft Study

Breakthrough in Kidney Transplant Monitoring: PRISM MarketView Spotlights Oncocyte’s VitaGraft Study

Jun 3, 2024

New York, June 3, 2024—Oncocyte’s (Nasdaq: OCX) VitaGraft Kidney™ diagnostic test for transplant monitoring has shown promising results in a Phase 2 clinical trial, published in the prestigious New England Journal of Medicine. The trial evaluated the test's effectiveness in monitoring graft health in patients with antibody-mediated rejection (AMR), a leading cause of kidney transplant failure. The study's positive outcomes highlight new clinical uses for VitaGraft Kidney, including therapeutic...

Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus

Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus

May 31, 2024

Clinical testing of LP-310 expected to commence in mid-2024 Patient recruitment is underway for Phase 2a multicenter, dose-ranging study PITTSBURGH, PA., May 31, 2024 -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced the successful completion of its first Site Initiation Visit (SIV) for the Phase 2a trial evaluating LP-310 in the treatment...

Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus

Lipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 29, 2024

Abstract highlighting new preclinical data from LP-50 in non-muscle invasive bladder cancer PITTSBURGH, Pa., May 29, 2024 – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces an abstract publication at the 2024 American Society of Clinical Oncology (ASCO) annual meeting, taking place from May 31 - June 4 in Chicago, IL, and online. Lipella’s...

Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b

Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b

May 21, 2024

Share: Company to initiate Phase 2b clinical trial in lead asset, LP-10 in 2H 2024 Pittsburgh, PA, May 21, 2024 - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company, announced today the receipt of U.S. Food & Drug Administration (“FDA”) Type-C meeting guidance regarding the LP-10 (liposomal tacrolimus) clinical program. Lipella expects to initiate a Phase 2b clinical trial evaluating LP-10 as a treatment for hemorrhagic...

Digital Utilities Ventures Completes Feed Earth Now Merger – Accelerates Growth of Regenerative Agriculture Movement

Digital Utilities Ventures Completes Feed Earth Now Merger – Accelerates Growth of Regenerative Agriculture Movement

May 16, 2024

Mankato, Minnesota, May 16, 2024 - PRISM MediaWire - Digital Utilities Ventures, Inc. (OTC: DUTV) is pleased to announce the successful acquisition of Feed Earth Now, LLC. The consummation of this transaction is a significant step forward in DUTV's mission to leverage innovative, organic products to address global fertilizer shortages through the advancement of regenerative agriculture principles. Mark K. Gaalswyk, the enterprising DUTV CEO behind...

ONCOCYTE REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS

ONCOCYTE REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS

May 15, 2024

Conference Call on Wednesday, May 15, 2024, at 1:30 p.m. PT / 4:30 p.m. ET IRVINE, CA, May 15, 2024 - Oncocyte Corporation (NASDAQ: OCX), a precision diagnostics company, today reported financial results for the quarter ended March 31, 2024. Recent Highlights Announced global commercialization partnership with Bio-Rad Laboratories, Inc. On track to ship research use only (RUO) GraftAssureTM transplant monitoring test kits to initial customers in Asia, the U.S., and the EU in 2Q 2024. IVD...

BioStem Technologies Reports Record First Quarter Revenue of $41.9 Million

BioStem Technologies Reports Record First Quarter Revenue of $41.9 Million

May 14, 2024

Company Achieves Record-Breaking First Quarter Results for 2024, Marking the Launch of BioStem 2.0 Company Reports First Quarter EBITDA of $4.9 Million Project Continued Growth from Sales of AmnioWrap2 ® Financial Results Conference Call and Webcast on Tuesday, May 14, 2024, at 4:30 pm EDT POMPANO BEACH, FLORIDA, May 14, 2024—BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived...

ONCOCYTE REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS

Oncocyte to Announce First Quarter 2024 Financial Results

May 13, 2024

Conference Call and Webcast on Wednesday, May 15, 2024 at 1:30 p.m. PT / 4:30 p.m. ET IRVINE, CA, May 13, 2024 - Oncocyte Corporation (NASDAQ: OCX), a precision diagnostics company, announced today that the company will release its first quarter 2024 financial results on Wednesday, May 15, 2024, after U.S. market close. The company will host a conference call and webcast on Wednesday, May 15, 2024, at 4:30 p.m. Eastern Time to discuss its financial results and highlights. Interested parties...

BioStem Technologies Reports Record First Quarter Revenue of $41.9 Million

BioStem Technologies to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024

May 7, 2024

Conference Call on Tuesday, May 14th, at 4:30 pm ET POMPANO BEACH, FLORIDA, May 7, 2024—BioStem Technologies Inc. (OTC: BSEM), a leading biotechnology company focused on the development, manufacture, and commercialization of placental derived allografts for advanced wound care, announced today that it plans to release its first quarter 2024 financial results post-market on Tuesday, May 14, 2024. BioStem will host a conference call and webcast at 4:30 pm ET on Tuesday, May 14, 2024. The call...

BioStem Technologies Reports Record First Quarter Revenue of $41.9 Million

BioStem Technologies Granted Prioritized Examination for Wound Healing Patent

May 6, 2024

POMPANO BEACH, FLORIDA, May 6, 2024—BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived allografts for advanced wound care, today announced that the United States Patent and Trademark Office (USPTO) has granted the Company’s request for Prioritized Examination for its application for U.S. Patent 18/290,914 titled STERILE HUMAN PLACENTAL ALLOGRAFTS AND METHODS OF MAKING THEREOF. “As we...

BioStem Technologies Reports Record First Quarter Revenue of $41.9 Million

BioStem Technologies Retains Clinical Research Industry Veteran Nick McCoy to Lead DFU and VLU trials for BioREtain Allografts

Apr 30, 2024

POMPANO BEACH, FLORIDA, April 30, 2024—BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived tissue allografts for advanced wound care, today announced that it has retained the services of Mr. Nick McCoy, who will lead BioStem’s Diabetic Foot Ulcer (DFU) and Venous Leg Ulcer (VLU) clinical trials process as a consultant to the Company. BioStem’s clinical focus on completing these...

PRISM MarketView – Weekly Market Report – April 26, 2024

PRISM MarketView – Weekly Market Report – April 26, 2024

Apr 26, 2024

PRISM Market Pulse: Equities Rally Amid Mixed Big Tech Earnings; Economic Shifts and Sector-Specific Highlights New York, N.Y., April 26, 2024 - PRISM MarketView - Equities were higher through the morning into midday trading as the S&P 500 and Nasdaq are set to snap their three- and four-week losing streaks. Big tech was the topic of Street-talk this week as some of the Magnificent Seven reported earnings. The reports produced mixed and opposite reactions by the Street as Tesla (TSLA)...